NASDAQ : IDXX
IDEXX Laboratories, Inc. — Key statistics
Healthcare · Diagnostics & Research · United States
Last price 551.21 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 43.42B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 43.42B |
| Enterprise Value | 44.32B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 78.78M |
| Shares Outstanding | 78.78M |
| Shares Change (YoY) | -2.40% |
| Shares Change (QoQ) | -1.06% |
| Owned by Insiders (%) | 0.26% |
| Owned by Institutions (%) | 96.75% |
| Float | 78.50M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 38.76 |
| Forward PE | 35.13 |
| PS Ratio | 9.54 |
| Forward PS | 8.84 |
| PB Ratio | 26.96 |
| P/TBV Ratio | 39.35 |
| P/FCF Ratio | 34.62 |
| P/OCF Ratio | 31.66 |
| PEG Ratio | 2.34 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 38.89 |
| EV / Sales | 9.73 |
| EV / EBITDA | 27.33 |
| EV / EBIT | 30.20 |
| EV / FCF | 35.34 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.17 |
| Quick Ratio | 0.73 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | 0.66 |
| Debt / FCF | 0.87 |
| Interest Coverage | 38.84 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 74.21% |
| Return on Assets (ROA) | 27.09% |
| Return on Invested Capital (ROIC) | 47.23% |
| Return on Capital Employed (ROCE) | 68.11% |
| Weighted Average Cost of Capital (WACC) | 12.52% |
| Revenue Per Employee | $413,929 |
| Profits Per Employee | $103,605 |
| Employee Count | 11,000 |
| Asset Turnover | 1.34 |
| Inventory Turnover | 4.36 |
Taxes
| Measure | Value |
|---|
| Income Tax | 284.76M |
| Effective Tax Rate | 19.99% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.55 |
| 52-Week Price Change | -12.18% |
| 50-Day Moving Average | 534.27 |
| 200-Day Moving Average | 572.62 |
| Relative Strength Index (RSI) | 52.39 |
| Average Volume (20 Days) | 562,125 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.93M |
| Short Previous Month | 1.94M |
| Short % of Shares Out | 2.45% |
| Short % of Float | 2.46% |
| Short Ratio (days to cover) | 3.68 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.55B |
| Gross Profit | 2.84B |
| Operating Income | 1.47B |
| Pretax Income | 1.42B |
| Net Income | 1.14B |
| EBITDA | 1.62B |
| EBIT | 1.47B |
| Earnings Per Share (EPS) | $14.22 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 196.93M |
| Total Debt | 1.10B |
| Net Cash | -899.15M |
| Net Cash Per Share | -$11.41 |
| Equity (Book Value) | 1.61B |
| Book Value Per Share | 20.44 |
| Working Capital | 221.82M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 1.37B |
| Capital Expenditures | -117.18M |
| Depreciation & Amortization | 154.08M |
| Net Borrowing | -135.00M |
| Free Cash Flow | 1.25B |
| FCF Per Share | $15.92 |
Margins
| Measure | Value |
|---|
| Gross Margin | 62.45% |
| Operating Margin | 32.23% |
| Pretax Margin | 31.28% |
| Profit Margin | 25.03% |
| EBITDA Margin | 35.62% |
| EBIT Margin | 32.23% |
| FCF Margin | 27.55% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 2.40% |
| Shareholder Yield | 2.40% |
| Earnings Yield | 2.58% |
| FCF Yield | 2.89% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $694.42 |
| Price Target Difference | 25.98% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 9.24% |
| EPS Growth Forecast (3Y) | 13.08% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 16, 2015 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 21.94 |
| Piotroski F-Score | 8 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |